Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
7.51
-0.21 (-2.72%)
Dec 20, 2024, 4:00 PM EST - Market closed
Grifols Revenue
Grifols had revenue of 1.79B EUR in the quarter ending September 30, 2024, with 12.24% growth. This brings the company's revenue in the last twelve months to 7.01B, up 7.21% year-over-year. In the year 2023, Grifols had annual revenue of 6.59B with 8.71% growth.
Revenue (ttm)
7.01B EUR
Revenue Growth
+7.21%
P/S Ratio
n/a
Revenue / Employee
295,156 EUR
Employees
23,737
Market Cap
5.99B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
| Dec 31, 2022 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | 5.10B | 611.97M | 13.64% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch + Lomb | 4.68B |
| Elanco Animal Health | 4.45B |
| Lantheus Holdings | 1.50B |
| Stevanato Group | 1.22B |
| Halozyme Therapeutics | 947.36M |
| Waystar Holding | 906.14M |
| Legend Biotech | 520.18M |
| Revolution Medicines | 742.00K |
GRFS News
- 11 days ago - Flat Footed Calls for Prompt Governance Overhaul at Grifols - Business Wire
- 16 days ago - Spain's market regulator sees signs of manipulation in Grifols-Gotham dispute - Reuters
- 17 days ago - Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga - Business Wire
- 17 days ago - Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols - Business Wire
- 22 days ago - Grifols: More Attractive Than In A Very Long Time - Seeking Alpha
- 22 days ago - Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday? - Benzinga
- 24 days ago - Grifols shares tumble after report on Brookfield abandoning takeover plan - Reuters
- 4 weeks ago - Grifols: Brookfields potential $6.8 bln offer undervalues the firm - Reuters